Key facts
- This page summarizes David Scott Jones's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Feb 2024, 17:15.
David Scott Jones - 02 Feb 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)
- Reporting relationship
- SVP & Chief Commercial Officer
- Issuer ticker
- EYPT
- Reported as of
- 02 Feb 2024
- Net transaction value
- -$3,557
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2024, 17:15:56 UTC
- Prior SEC filing
- 29 Jan 2024
- Next SEC filing
- 13 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron Honig, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Scott Jones filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 05 Feb 2024.
Change
- Previous filing in this sequence was filed on 29 Jan 2024.
- Current net transaction value: -$3,557.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EYPT
transaction
Common Stock
Options Exercise
- Transaction value
- $2,397
- Shares
- +209
- Change %
- +0.55%
- Price
- $11.47
- Shares after
- 38,171
- Date
- 02 Feb 2024
- Ownership
- Direct
EYPT
transaction
Common Stock
Sale
- Transaction value
- $5,954
- Shares
- -209
- Change %
- -0.55%
- Price
- $28.49
- Shares after
- 37,962
- Date
- 02 Feb 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -209
- Change %
- -4.6%
- Price
- $0.000000
- Shares after
- 4,375
- Date
- 02 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 209
- Exercise price
- $11.47
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 1 footnote
Footnote F1
The option to purchase vests and becomes exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.